Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.

Journal

British journal of cancer

ISSN: 1532-1827

Titre abrégé: Br J Cancer

Pays: England

ID NLM: 0370635

Informations de publication

Date de publication:
28 Sep 2024

Historique:

received: 05 03 2024

accepted: 13 09 2024

revised: 09 09 2024

medline: 29 9 2024

pubmed: 29 9 2024

entrez: 28 9 2024

Statut: aheadofprint

Résumé

Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive. We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors. Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.

Sections du résumé

BACKGROUND BACKGROUND

Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.

METHODS METHODS

We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.

RESULTS RESULTS

Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR

CONCLUSIONS CONCLUSIONS

Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.

Identifiants

DOI: 10.1038/s41416-024-02858-6 PMID: 39342063

pubmed: 39342063

doi: 10.1038/s41416-024-02858-6

pii: 10.1038/s41416-024-02858-6

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)

ID : FI19/00197

Organisme : Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer)

ID : PRYES211366AGUD

Informations de copyright

Références

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer today. International Agency for Research on Cancer. 2020. http://gco.iarc.fr/today . Accessed 13 Jun 2023.

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25:1822–32.

doi: 10.1038/s41591-019-0675-0 pubmed: 31806905 pmcid: 7147972

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

doi: 10.1016/j.cell.2011.02.013 pubmed: 21376230

Abubakar M, Zhang J, Ahearn TU, Koka H, Guo C, Lawrence SM, et al. Tumor-associated stromal cellular density as a predictor of recurrence and mortality in breast cancer: results from ethnically-diverse study populations. Cancer Epidemiol Biomark Prev. 2021;30:1397–407.

doi: 10.1158/1055-9965.EPI-21-0055

Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13:R55.

doi: 10.1186/bcr2891 pubmed: 21639875 pmcid: 3218944

Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–44.

doi: 10.1200/JCO.2008.18.9068 pubmed: 19470939 pmcid: 2717751

Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS, et al. Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer. 2007;96:891–5.

doi: 10.1038/sj.bjc.6603682 pubmed: 17375036 pmcid: 2360103

Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomark Prev. 2008;17:1719–22.

doi: 10.1158/1055-9965.EPI-07-0654

Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113–24.

doi: 10.1079/PHN2002394 pubmed: 12639222

Cairat M, Rinaldi S, Navionis AS, Romieu I, Biessy C, Viallon V, et al. Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort. BMC Med. 2022;20:118.

doi: 10.1186/s12916-022-02319-y pubmed: 35430795 pmcid: 9014562

Agudo A, Cayssials V, Bonet C, Tjønneland A, Overvad K, Boutron-Ruault MC, et al. Inflammatory potential of the diet and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr. 2018;107:607–16.

doi: 10.1093/ajcn/nqy002 pubmed: 29635497

Castro-Espin C, Agudo A, Bonet C, Katzke V, Turzanski-Fortner R, Aleksandrova K, et al. Inflammatory potential of the diet and risk of breast cancer in the European Investigation into Cancer and Nutrition (EPIC) study. Eur J Epidemiol. 2021;36:953–64.

doi: 10.1007/s10654-021-00772-2 pubmed: 34148186

Castro-Espin C, Bonet C, Crous-Bou M, Katzke V, Le Cornet C, Jannasch F, et al. Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis: results from a cohort study. Br J Cancer. 2023;128:1301–10.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

doi: 10.1080/01621459.1999.10474144

Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904–10.

doi: 10.1016/j.ctrv.2012.04.007 pubmed: 22651903

Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015;35:1–16.

doi: 10.1089/jir.2014.0026 pubmed: 25068787 pmcid: 4291218

Lin S, Gan Z, Han K, Yao Y, Min D. Interleukin-6 as a prognostic marker for breast cancer: a meta-analysis. Tumori. 2015;101:535–41.

doi: 10.5301/tj.5000357 pubmed: 26045123

Tsoi H, Man EPS, Chau KM, Khoo US. Targeting the IL-6/STAT3 signalling cascade to reverse tamoxifen resistance in estrogen receptor positive breast cancer. Cancers. 2021;13:1511.

doi: 10.3390/cancers13071511 pubmed: 33806019 pmcid: 8036560

Chen J, Wei Y, Yang W, Huang Q, Chen Y, Zeng K, et al. IL-6: the link between inflammation, immunity and breast cancer. Front Oncol. 2022;12:903800.

doi: 10.3389/fonc.2022.903800 pubmed: 35924148 pmcid: 9341216

Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103:642–6.

doi: 10.1002/ijc.10833 pubmed: 12494472

Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999;19:1427–32.

pubmed: 10365118

Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 2003;88:1721–6.

doi: 10.1038/sj.bjc.6600956 pubmed: 12771987 pmcid: 2377148

Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol Immunother. 2018;67:537–49.

doi: 10.1007/s00262-017-2106-8 pubmed: 29256156

Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor necrosis factor α blockade: an opportunity to tackle breast cancer. Front Oncol. 2020;10:584.

doi: 10.3389/fonc.2020.00584 pubmed: 32391269 pmcid: 7189060

Merendino RA, Arena A, Capozza AB, Chillemi S, Mesiti M. Serum levels of interleukin-10 in patients affected by breast cancer. Immunol Lett. 1996;53:59–60.

doi: 10.1016/0165-2478(96)02598-9 pubmed: 8946219

Hamidullah, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2012;133:11–21.

doi: 10.1007/s10549-011-1855-x pubmed: 22057973

Baumgarten SC, Frasor J. Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol. 2012;26:360–71.

doi: 10.1210/me.2011-1302 pubmed: 22301780 pmcid: 3286192

Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, et al. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis. 2015;36:1121–8.

doi: 10.1093/carcin/bgv096 pubmed: 26130675

Villaseñor A, Flatt SW, Marinac C, Natarajan L, Pierce JP, Patterson RE. Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomark Prev. 2014;23:189–99.

doi: 10.1158/1055-9965.EPI-13-0852

Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, et al. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat. 2016;155:345–54.

doi: 10.1007/s10549-015-3671-1 pubmed: 26740213

Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295.

doi: 10.1101/cshperspect.a016295 pubmed: 25190079 pmcid: 4176007

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

doi: 10.1038/nature07205 pubmed: 18650914

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

doi: 10.1016/S0140-6736(00)04046-0 pubmed: 11229684

Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011;1229:45–52.

doi: 10.1111/j.1749-6632.2011.06096.x pubmed: 21793838

Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013;24:2506–14.

doi: 10.1093/annonc/mdt224 pubmed: 23793035 pmcid: 3784334

Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.

doi: 10.1056/NEJMoa1008862 pubmed: 21366474 pmcid: 4109980

Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, et al. Temporal reliability of cytokines and growth factors in EDTA plasma. BMC Res Notes. 2010;3:302.

doi: 10.1186/1756-0500-3-302 pubmed: 21073739 pmcid: 2997094